Published in J Neurol on January 31, 2008
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
High field MRI in the diagnosis of multiple sclerosis: high field-high yield? Neuroradiology (2009) 1.24
Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management. CNS Drugs (2009) 1.14
Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol (2012) 0.94
Cortical lesions and cognitive impairment in multiple sclerosis. Neurol Sci (2010) 0.84
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation. Magn Reson Imaging (2012) 0.82
Grey matter lesions in MS: from histology to clinical implications. Prion (2012) 0.81
Multiple sclerosis: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal (2013) 0.80
Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. Neurol Sci (2011) 0.78
Association between multiple sclerosis and epilepsy: large population-based record-linkage studies. BMC Neurol (2013) 0.78
A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons. Elife (2016) 0.75
Three immune-mediated disease models induced by Theiler's virus: Multiple sclerosis, seizures and myocarditis. Clin Exp Neuroimmunol (2016) 0.75
Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis. Neurol Sci (2017) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 4.06
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol (2007) 2.07
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol (2007) 1.76
Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol (2007) 1.51
[Epilepsy as the first sign of multiple sclerosis]. Rev Neurol (1997) 1.39
Cortical lesions and brain atrophy in MS. J Neurol Sci (2005) 1.24
Grey matter pathology in multiple sclerosis. Acta Neurol Scand Suppl (2006) 1.12
Double inversion recovery imaging of the brain: initial experience and comparison with fluid attenuated inversion recovery imaging. Magn Reson Imaging (1998) 1.06
Epilepsy and multiple sclerosis. Epilepsy Behav (2003) 0.99
Prevalence and prognosis of epilepsy in patients with multiple sclerosis. Epilepsia (1987) 0.97
Imaging the neocortex in epilepsy with double inversion recovery imaging. Neuroimage (2006) 0.95
Epilepsy in multiple sclerosis. Eur Neurol (1990) 0.90
Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. Epilepsia (1998) 0.87
Epileptic and non-epileptic seizures in multiple sclerosis. J Neurol (2001) 0.86
Epileptic seizures in patients with multiple sclerosis. Is the prognosis of epilepsy underestimated? Seizure (1997) 0.86
Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. Mult Scler (2003) 0.85
Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Mult Scler (1996) 0.83
Seizures due to multiple sclerosis: seven patients with MRI correlations. J Neurol Neurosurg Psychiatry (1993) 0.81
Simple dysphasic seizures as the sole manifestation of relapse in multiple sclerosis. Epilepsia (1995) 0.81
Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage (2004) 49.54
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2013) 3.28
No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol (2011) 3.07
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol (2014) 2.51
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol (2009) 2.20
Jugular veins in transient global amnesia: innocent bystanders. Stroke (2012) 2.19
Right-to-left shunt in CADASIL patients: prevalence and correlation with clinical and MRI findings. Stroke (2008) 2.07
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol (2007) 2.07
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yes. Mult Scler (2014) 1.99
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Age-related changes in grey and white matter structure throughout adulthood. Neuroimage (2010) 1.85
Blood oxygenation level dependent contrast resting state networks are relevant to functional activity in the neocortical sensorimotor system. Exp Brain Res (2005) 1.84
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
The relationship between diffuse axonal damage and fatigue in multiple sclerosis. Arch Neurol (2004) 1.76
Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study. Neurology (2013) 1.72
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Brain metabolic changes suggestive of axonal damage in radiologically isolated syndrome. Neurology (2013) 1.61
Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis. J Neurol Sci (2009) 1.59
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol (2007) 1.51
Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol (2008) 1.48
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol (2010) 1.46
Female form of persistent müllerian duct syndrome: MDCT findings. Clin Imaging (2008) 1.45
Manifestations of early brain recovery associated with abstinence from alcoholism. Brain (2007) 1.43
Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp (2011) 1.42
Severe relapses under fingolimod treatment prescribed after natalizumab. Neurology (2012) 1.40
Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol (2004) 1.38
Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage (2007) 1.37
Cortical lesion load associates with progression of disability in multiple sclerosis. Brain (2012) 1.26
Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.26
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol (2011) 1.25
Age-related changes in conventional, magnetization transfer, and diffusion-tensor MR imaging findings: study with whole-brain tissue histogram analysis. Radiology (2003) 1.24
Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler (2010) 1.22
Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol (2007) 1.22
MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet (2009) 1.19
NF-kappaB dimers in the regulation of neuronal survival. Int Rev Neurobiol (2009) 1.15
Enhanced brain extraction improves the accuracy of brain atrophy estimation. Neuroimage (2008) 1.13
Neurological complications of celiac disease and autoimmune mechanisms: a prospective study. J Neuroimmunol (2008) 1.13
Cortical lesion counts by double inversion recovery should be part of the MRI monitoring process for all MS patients: yes. Mult Scler (2014) 1.12
NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J Neurochem (2009) 1.11
Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother (2011) 1.10
Akt increases sarcoplasmic reticulum Ca2+ cycling by direct phosphorylation of phospholamban at Thr17. J Biol Chem (2009) 1.09
Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease. J Neurochem (2011) 1.09
Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain (2006) 1.09
No MRI evidence of cortical lesions in neuromyelitis optica. Neurology (2012) 1.08
Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler (2010) 1.07
A kidney tumor in an adolescent with severe hypertension and hypokalemia: an uncommon case--case report and review of the literature on reninoma. Urol Int (2010) 1.07
Post-ischemic brain damage: NF-kappaB dimer heterogeneity as a molecular determinant of neuron vulnerability. FEBS J (2009) 1.06
Immunogenicity of interferon beta: differences among products. J Neurol (2004) 1.05
Defining and scoring response to IFN-β in multiple sclerosis. Nat Rev Neurol (2013) 1.04
Acute unilateral visual loss as the first symptom of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Arch Neurol (2004) 1.03
Intercenter differences in diffusion tensor MRI acquisition. J Magn Reson Imaging (2010) 1.01
The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol (2004) 1.00
Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage (2008) 0.99